Dr. Abbey Recognized as a 2023 Top 10 Reviewer for Ophthalmic Surgery Lasers + Imaging Retina Medical Journal
The medical journal Ophthalmic Surgery Lasers + Imaging Retina (OSLI Retina) recently recognized Texas Retina Associates’ Ashkan M. Abbey, MD as a “2023 Top 10 Reviewer” in recognition of the quantity, quality
read more
Dr. Abbey Featured as a Panelist in Retina Times Article on Secondary IOL Placement Surgery
In the Winter 2023 issue of Retina Times published by the American Society of Retina Specialists (ASRS), Texas Retina Associates’ Ashkan M. Abbey, MD, was featured in an article titled, “Managing the
read more
Dr. Abbey Taught a Course at the American Academy of Ophthalmology 2023 Annual Meeting
On November 6, Texas Retina Associates’ Ashkan M. Abbey, MD, taught a continuing medical education (CME) course titled, “Secondary IOL Techniques for Retinal Specialists,” at AAO 2023, the annual meeting of the
read more
Three New Clinical Trials Available at Texas Retina
Medical researchers continue to make significant advances in the diagnosis and treatment of retinal conditions, and our physicians remain committed to participating in clinical trials that will improve care for our patients.
read more
New Treatments Available for Geographic Atrophy
We know geographic atrophy (GA) can negatively impact patients’ quality of life and independence. While it still cannot be cured, Texas Retina is excited to finally have two new GA treatment options
read more Dr. Abbey Publishes Case Report on Macular Hole Closure with Intravitreal Dexamethasone Implant
In the September 2023 issue of the peer-reviewed medical journal Ophthalmic Surgery, Lasers and Imaging Retina, Texas Retina’s Ashkan Abbey, MD, describes the use of a dexamethasone intravitreal implant to close a
read more Dr. Abbey Publishes Research on Effectiveness of a Long-acting Injectable Steroid for Patients with Cystoid Macular Edema After Vitrectomy
Long-acting injectable steroids have emerged as a new way to treat chronic intraocular inflammation and cystoid macular edema (CME) that reduces the treatment frequency and burden for retina patients. Texas Retina’s Ashkan
read more Dr. Abbey Presented at the American Society of Retina Specialists 2023 Annual Meeting
Texas Retina Associates’ Ashkan M. Abbey, MD, recently presented at the 41st Annual Scientific Meeting of the American Society of Retina Specialists (ASRS) held in Seattle. ASRS is the largest organization of
read more Texas Retina Associates First in U.S. to Dose a Patient in the Phase 2 SIGLEC Trial
On June 1, 2023, Ashkan Abbey, MD, dosed the first patient in the Phase II SIGLEC Trial, a clinical study evaluating AVD-104, a potential new treatment for geographic atrophy (GA) from age-related
read more
Dr. Abbey Presents Phase 1 DAVIO Clinical Trial Results to the Association for Research in Vision and Ophthalmology
Dr. Abbey presented the results from the Phase 1 DAVIO trial at ARVO 2023, the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO). The trial was a first-in-human
read more